Akshay Hanikhindi

September 14, 2020
PrECOG logo

Trial Results: PALbociclib CoLlaborative Adjuvant Study (PALLAS)

A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence